Guided Therapeutics (GTHP) Net Equity Issued and Repurchased (2017 - 2024)

Guided Therapeutics (GTHP) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $535000.0 in Q4 2024.

• For the quarter ending Q4 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $535000.0; the trailing twelve-month figure through Dec 2024 stood at $1.9 million (up 38.43% YoY), and the FY2025 full-year result was $567000.0, down 32.1% from the prior year.
• Net Equity Issued and Repurchased advanced to $535000.0 in Q4 2024, from -$4000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $1.4 million in Q3 2022 to a low of -$125000.0 in Q4 2021.
• A 4-year average of $275285.7 and a median of $103000.0 in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased rose 21.36% in 2021 and jumped 96.8% in 2022, its largest moves.
• Tracing GTHP's Net Equity Issued and Repurchased over 4 years: stood at -$103000.0 in 2020, then fell by 21.36% to -$125000.0 in 2021, then jumped by 96.8% to -$4000.0 in 2022, then jumped by 13475.0% to $535000.0 in 2024.
• Business Quant data shows GTHP's Net Equity Issued and Repurchased at $535000.0 in Q4 2024, -$4000.0 in Q4 2022, and $1.4 million in Q3 2022.